Q2 Pharma has reached an exclusive agreement for an option for a license from Case Western Reserve University to commercialize antivirulence agents discovered in the laboratory of Menachem Shoham, PhD.

  1. Shoham and M. Greenberg. Preventing the spread of infectious diseases: antivirulents vs. antibiotics. Future Microbiology. In the press.

  2. Kuo D, Yu G, Hoch W, Gabay D, Long L, Ghannoum M, Nagy N, Harding CV, Viswanathan R, Shoham M. (2015). Novel quorum-quenching agents promote methicillin-resistant Staphylococcus aureus (MRSA) wound healing and sensitize MRSA to β-lactam antibiotics. Antimicrob Agents Chemother. 59:1512-8. doi: 10.1128/AAC.04767-14. PMID: 25534736.

  3. Yu G, Kuo D, Shoham M, Viswanathan R. (2014). Combinatorial synthesis and in vitro evaluation of a biaryl hydroxyketone library as antivirulence agents against MRSA. ACS Comb Sci.16:85-91. doi: 10.1021/co400142t. PMID: 24372007.

  4. Khodaverdian V, Pesho M, Truitt B, Bollinger L, Patel P, Nithianantham S, Yu G, Delaney E, Jankowsky E, Shoham M. (2013). Discovery of antivirulence agents against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 57:3645-52. doi: 10.1128/AAC.00269-13. PMID: 23689713.

  5. Shoham. (2011). Anti-virulence agents against MRSA .Future Med Chem 3:775-777. PMID: 21644821.